This article was originally published in The Tan Sheet
Schering-Plough TV spot with tagline "Clarity for mind, body and spirit" and scenes of people frolicking in fields breaks Dec. 12. Ad campaign celebrates "'new generation' of non-drowsy allergy relief" and features "multi-generational cast that reinforces the brand's appropriateness and efficacy for children and adults," 1S-P press release says. Retail price of 10 mg tablets is 90¢-$1.35/tablet, Schering says. In the D.C. area, 10 mg tablets (20-counts) are selling for about $23, RediTabs (10) for $14-$15, and D 24-Hour (10) for $14-$15. Separately, S-P notes its Nov. 27 statement that all loratadine formulations can now only be sold OTC was unrelated to its earlier announcement of a "market transition period during which" Rx activity would continue. Transition phase represents undefined period following OTC approval when patients can refill a prescription with Rx product already in commerce, S-P says (2"The Tan Sheet" Dec. 2, 2002, p. 3)...
You may also be interested in...
Wyeth Consumer Healthcare is staking a claim to the OTC loratadine market with Alavert pricing of 56¢ to $1 per orally disintegrating tablet and high-value coupons
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.